Vagus Nerve Stimulation for PTSD: From Fear Circuits to Clinical Breakthroughs

Introduction: The Treatment Gap in PTSD

Post-traumatic stress disorder (PTSD) affects approximately 6–7% of the general population at some point in their lives, with substantially higher rates among military personnel — current prevalence among veterans of Operations Enduring Freedom and Iraqi Freedom reaches 15%, with lifetime prevalence approaching 29% (National Center for PTSD, 2024). The condition is characterised by intrusive re-experiencing of traumatic events, persistent avoidance of trauma-related stimuli, negative alterations in cognition and mood, and marked changes in arousal and reactivity.

Despite decades of research, the treatment gap in PTSD remains formidable. Approximately one-third of patients are classified as treatment-resistant. Non-response rates for trauma-focused cognitive behavioural therapy may be as high as 50%, and for selective serotonin reuptake inhibitors (SSRIs) — the only FDA-approved pharmacological class for PTSD — approximately 20–40% of patients fail to respond adequately (Levi et al., 2022). Of 100 patients receiving trauma-focused therapy, only 53 will achieve remission; with medication alone, only 42 will. Critically, current treatments are least effective for intrusion symptoms — the hallmark flashbacks and involuntary re-experiencing that define the disorder.

This treatment gap has driven a growing body of research into vagus nerve stimulation (VNS) as a novel approach to PTSD. What makes VNS particularly compelling for this condition is not simply that it is another neuromodulation technique, but that its mechanism of action maps directly onto the neural circuits that are dysregulated in PTSD — the fear extinction pathways, the autonomic nervous system, the hypothalamic-pituitary-adrenal (HPA) axis, and the inflammatory response.

Why the Vagus Nerve? The Neurobiology of PTSD

To understand why VNS is a rational intervention for PTSD, it is necessary to understand what goes wrong in the brain and body of a person with PTSD — and how the vagus nerve intersects with each of these systems.

A Disorder of Failed Fear Extinction

At its core, PTSD can be understood as a failure of fear extinction — the process by which the brain learns that a previously threatening stimulus is no longer dangerous. In healthy individuals, exposure to trauma-related cues without further harm gradually weakens the fear response through extinction learning, mediated by the ventromedial prefrontal cortex (vmPFC) exerting inhibitory control over the amygdala.

In PTSD, this process is profoundly impaired. Neuroimaging studies consistently show:

- Hypoactivation of the vmPFC — the brain region responsible for suppressing fear responses
- Hyperactivation of the amygdala — the brain's threat detection centre
- Altered hippocampal function — impairing the contextualisation of fear memories (distinguishing "then and there" from "here and now")

This neural signature means that individuals with PTSD cannot efficiently learn safety. The fear response persists long after the threat has passed, driving the intrusive memories, hypervigilance, and exaggerated startle that define the disorder.

Autonomic Dysregulation: Stuck in Fight-or-Flight

PTSD is also characterised by chronic autonomic nervous system dysregulation — specifically, a sustained shift toward sympathetic (fight-or-flight) dominance and a withdrawal of parasympathetic (rest-and-digest) activity. This manifests as:

- Reduced heart rate variability (HRV), reflecting diminished vagal tone
- Elevated resting heart rate and blood pressure
- Exaggerated startle responses
- Chronic hypervigilance and sleep disturbance

The vagus nerve is the primary conduit of parasympathetic activity. Its diminished function in PTSD is not merely a symptom — it is part of the pathophysiology that maintains the disorder. This autonomic imbalance is shared with other conditions in which VNS has shown promise, including anxiety and depression — two disorders that frequently co-occur with PTSD.

Chronic Inflammation

A growing body of evidence links PTSD to chronic low-grade inflammation, with elevated levels of interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-alpha), interferon-gamma (IFN-gamma), and C-reactive protein (CRP) observed in PTSD populations (Michopoulos et al., 2017). Given the well-established role of the vagus nerve in regulating inflammation through the cholinergic anti-inflammatory pathway (Tracey, 2002), this inflammatory component represents another rational target for VNS.

HPA Axis Dysregulation

The hypothalamic-pituitary-adrenal (HPA) axis — the body's central stress response system — is dysregulated in PTSD. Direct anatomical pathways exist between the nucleus tractus solitarius (NTS), the first relay station for vagal afferents in the brainstem, and inhibitory GABAergic neurons surrounding the paraventricular nucleus (PVN), the primary site of corticotropin-releasing hormone (CRH) production. This provides a neuroanatomical substrate by which VNS may modulate the stress hormone cascade.

The Mechanism: How VNS Targets the PTSD Circuit

When the vagus nerve is stimulated — whether through an implanted device, a transcutaneous cervical stimulator, or an auricular electrode — electrical signals travel along vagal afferent fibres to the nucleus tractus solitarius (NTS) in the brainstem. From the NTS, projections fan out to three critical neuromodulatory centres:

1. The locus coeruleus (LC) — the brain's primary source of norepinephrine
2. The dorsal raphe nucleus — a major source of serotonin
3. The nucleus basalis of Meynert — the primary source of cortical acetylcholine

These three neurotransmitter systems — norepinephrine, serotonin, and acetylcholine — are precisely the modulators that govern synaptic plasticity, memory consolidation, and the strengthening of new learning. When VNS activates these systems during fear extinction (or during exposure therapy, its clinical analogue), it creates a neurochemical environment that is optimally primed for the formation and consolidation of new safety memories.

The Norepinephrine Hypothesis

The role of norepinephrine is particularly central. The locus coeruleus projects widely to the prefrontal cortex, amygdala, and hippocampus — the triad of structures most implicated in PTSD. VNS-induced norepinephrine release in the amygdala enhances the consolidation of extinction memories, while norepinephrine in the prefrontal cortex strengthens top-down inhibitory control over amygdala reactivity.

Critically, a 2024 preclinical study by Noble et al. provided direct causal evidence for this pathway: optogenetic inhibition of the locus coeruleus completely blocked VNS-induced enhancement of fear extinction in rats. Without the locus coeruleus, VNS lost its therapeutic effect — confirming that noradrenergic signalling is not merely correlated with but essential for VNS's fear extinction-enhancing properties (Noble et al., 2024).

VNS-Induced Neuroplasticity

Beyond acute neuromodulation, VNS engages mediators of structural and synaptic plasticity: brain-derived neurotrophic factor (BDNF), fibroblast growth factor (FGF), NMDA receptor subunits, Arc protein, phosphorylated CaMKII, and TrkB receptors (Follesa et al., 2007). These molecular signals strengthen synaptic connections and promote the reorganisation of neural circuits — transforming a temporary learning event (a single exposure therapy session) into durable circuit-level change.

The convergence of extinction-evoked neuronal activity and phasic VNS-induced neuromodulation is hypothesised to strengthen neuronal processes in a temporally specific manner — enhancing precisely those circuits that are active during therapeutic learning.

Preclinical Evidence: The UT Dallas Fear Extinction Programme

Some of the most compelling evidence for VNS in PTSD comes from the laboratory of Michael Kilgard and colleagues at the University of Texas at Dallas, whose systematic preclinical programme has built a translational bridge from bench to bedside.

Noble et al. (2017): The Foundational Study

In the study that launched the translational programme, Noble et al. demonstrated that VNS paired with extinction training reduced conditioned freezing by 70% compared to sham stimulation in rats. VNS reversed extinction impairments and attenuated the reinstatement of conditioned fear responses. Most strikingly, delivery of VNS during extinction eliminated PTSD-like symptoms — anxiety, hyperarousal, and social avoidance — for more than one week after treatment cessation (Noble et al., 2017).

Noble et al. (2019): The PTSD Model

Using the single prolonged stress protocol — a validated model that produces PTSD-like extinction impairments through restraint, forced swim, loss of consciousness, and prolonged social isolation — Noble et al. showed that VNS reversed extinction impairments even in this more severe model. VNS-treated rats also demonstrated generalisation of extinction to conditioned stimuli not presented during treatment, suggesting that VNS does not merely strengthen specific extinction memories but may enhance the broader capacity for safety learning (Noble et al., 2019).

Noble et al. (2022): Timing Matters

A critical follow-up study established that VNS must be delivered during fear memory recall — within a narrow temporal window around conditioned stimulus onset — to enhance extinction. VNS delivered outside this window was ineffective. This finding has direct clinical implications: it supports the rationale for pairing VNS with exposure therapy sessions rather than using VNS as a standalone treatment (Noble et al., 2022).

Peña et al. (2014): Circuit-Level Evidence

Using electrophysiological recordings, Peña et al. demonstrated that VNS promotes plasticity in the infralimbic prefrontal cortex to basolateral amygdala pathway — the precise circuit that mediates extinction learning and that is dysfunctional in PTSD (Peña et al., 2014).

Clinical Evidence: From Small Trials to Landmark Results

The Emory–Georgia Tech Programme: Transcutaneous Cervical VNS

The most extensive body of clinical evidence for non-invasive VNS in PTSD comes from the collaboration between J. Douglas Bremner at Emory University and Omer Inan at the Georgia Institute of Technology, using the gammaCore transcutaneous cervical VNS (tcVNS) device.

Gurel et al. (2020) conducted a double-blind, sham-controlled trial in 25 patients with PTSD. Participants received active or sham tcVNS after exposure to personalised traumatic script stress over a three-day protocol. Active tcVNS significantly decreased sympathetic function as measured by heart rate, with effects persisting across multiple stress exposure and stimulation testing days (Gurel et al., 2020).

Wittbrodt et al. (2020) used high-resolution positron emission tomography (PET) to demonstrate that tcVNS produced significantly greater deactivation compared to sham in bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate — key regions of the fear and stress circuitry (Wittbrodt et al., 2020).

In a separate study, Wittbrodt, Gurel, and Bremner et al. (2020) showed that tcVNS blocked stress-induced increases in IL-6 and IFN-gamma in patients with PTSD, providing the first direct evidence that VNS can attenuate the inflammatory response to traumatic stress in a clinical PTSD population.

Bremner et al. (2021) extended these findings to a three-month treatment protocol: 20 PTSD patients were randomised to self-administered active or sham tcVNS twice daily for three months. Active tcVNS produced a 31% greater reduction in PTSD symptoms compared to sham, with significant decreases in hyperarousal symptoms and somatic anxiety. Brain imaging after three months confirmed that active tcVNS blocked the brain's response to traumatic scripts in regions mediating the fear response (Bremner et al., 2021).

These results led to the FDA granting gammaCore Breakthrough Device Designation for PTSD in January 2022 — an accelerated regulatory pathway reserved for technologies that address serious conditions with unmet needs.

The University of Florida Programme: Auricular VNS and Sleep

Lamb et al. (2017) conducted one of the earliest studies of transcutaneous auricular VNS (taVNS) in PTSD veterans, demonstrating that taVNS applied to the tragus improved vagal tone and moderated autonomic responses to startle in 22 combat veterans with PTSD and mild traumatic brain injury.

Bottari and Lamb et al. (2024) extended this work to sleep — a domain profoundly disrupted in PTSD. Using laboratory polysomnography in a crossover design, they found that taVNS at lights-out increased N3 (deep) sleep, decreased cyclic alternating pattern rate (indicating improved sleep stability), and increased parasympathetically mediated nocturnal autonomic activity in 13 veterans with PTSD. A subsequent 2025 study identified optimal stimulation parameters (20 Hz, 100 microseconds, 80% discomfort threshold) for maximising these sleep benefits (Bottari et al., 2025).

Powers et al. (2025): The Landmark Implanted VNS Trial

The most striking clinical result to date was published in Brain Stimulation in May 2025. Mark Powers, Seth Hays, Michael Kilgard, and colleagues at UT Dallas and Baylor University Medical Center conducted the first-in-human study of implanted VNS paired with prolonged exposure therapy for treatment-resistant PTSD.

Nine patients with moderate-to-severe treatment-resistant PTSD received a next-generation miniaturised implanted VNS device and underwent a standard 12-session course of prolonged exposure therapy with concurrent VNS delivery during exposure sessions.

The results were extraordinary: all nine participants no longer met criteria for a PTSD diagnosis after treatment. Benefits persisted at six-month follow-up after cessation of therapy. The treatment was safe and feasible, with no serious or unexpected device-related adverse events (Powers et al., 2025).

While the study was open-label and small, the magnitude of the response — 100% loss of diagnosis in treatment-resistant patients — is unprecedented in the PTSD treatment literature. A Phase 2 double-blind, placebo-controlled trial is currently underway in Dallas and Austin.

Approaches to VNS for PTSD

Three forms of VNS are being investigated for PTSD, each with distinct advantages:

Invasive / Implanted VNS (iVNS)

A surgically implanted pulse generator in the chest delivers stimulation via an electrode wrapped around the left cervical vagus nerve. This approach offers precise and consistent stimulation parameters and was used in the Powers et al. (2025) trial. Drawbacks include surgical risks, cost, and the permanence of implantation.

Transcutaneous Cervical VNS (tcVNS)

A handheld device (e.g., gammaCore) applied to the neck delivers mild electrical stimulation to the cervical vagus nerve through the skin. This is the approach used in the Emory–Georgia Tech programme and is the device that received FDA Breakthrough Device Designation for PTSD. It is portable and self-administered, though it requires the user to hold the device against the neck during each session.

Transcutaneous Auricular VNS (taVNS)

Stimulation of the auricular branch of the vagus nerve (ABVN) at the ear — typically at the tragus or cymba conchae — is the most accessible and affordable approach. It was used in the University of Florida sleep studies and is the focus of growing research interest. The cymba conchae has been shown to have denser vagal innervation than other auricular sites (Yakunina et al., 2017).

No head-to-head comparisons between these approaches exist for PTSD. Each may find its role: implanted VNS for severe, treatment-resistant cases where maximal efficacy is needed; transcutaneous approaches for broader clinical and potentially home-based applications.

What the Evidence Supports — and What Remains Uncertain

What the evidence supports:

- VNS (both invasive and transcutaneous) reduces sympathetic arousal in response to traumatic stress in PTSD patients
- tcVNS blocks stress-induced inflammatory responses (IL-6, IFN-gamma) in PTSD
- VNS decreases brain activity in fear and stress regions during trauma exposure
- VNS paired with extinction or exposure therapy enhances extinction learning and may produce lasting therapeutic effects — demonstrated in animal models and a Phase 1 human trial
- taVNS may improve sleep quality and autonomic function in PTSD veterans
- VNS is safe and well-tolerated in PTSD populations
- The locus coeruleus is a critical mediator of VNS's fear extinction-enhancing effects

What remains to be established:

- Efficacy in large-scale RCTs — No large, multi-site, double-blind trial has been completed. Sample sizes to date range from 9 to 25 patients.
- Optimal parameters — Stimulation frequency, intensity, duration, and timing relative to exposure therapy are still being optimised.
- Long-term durability — A 2025 systematic review in BJPsych Open found that parasympathetic effects appear short-lasting in some studies, though the Powers et al. trial showed benefits persisting at six months.
- Which form of VNS is best — tcVNS, taVNS, or iVNS for PTSD remains an open question without head-to-head data.
- Standalone vs. adjunct — Whether VNS has value on its own or must be paired with exposure therapy to achieve maximal benefit is not yet resolved, though preclinical evidence strongly favours the paired approach.
- Patient selection — Which PTSD subtypes benefit most, and how comorbidities (traumatic brain injury, depression, substance use) influence response, is largely unknown.

Comparison with Other Neuromodulation Approaches

VNS is not the only neuromodulation approach being explored for PTSD, and each offers a distinct mechanism:

Transcranial magnetic stimulation (TMS) uses magnetic fields to directly stimulate cortical areas (typically the dorsolateral or medial prefrontal cortex). It has a more established evidence base for PTSD than VNS, with several larger RCTs, and is FDA-cleared for depression and OCD. However, TMS requires clinic visits and specialised equipment.

Stellate ganglion block (SGB) involves injection of local anaesthetic into the stellate ganglion in the neck, directly blocking sympathetic overdrive. Multi-site RCTs have shown that SGB decreases PTSD symptom severity (Rae Olmsted et al., 2019). However, effects may be temporary and the procedure is invasive.

What distinguishes VNS is its dual action as both a bottom-up autonomic modulator and a top-down cortical plasticity enhancer. Unlike TMS (which directly stimulates cortex) or SGB (which blocks sympathetic ganglia), VNS operates through vagal afferents to simultaneously modulate multiple brain systems. When paired with exposure therapy, this dual action may both reduce the physiological burden of trauma exposure and enhance the neural plasticity required to form new safety memories — addressing the root mechanism of PTSD rather than merely suppressing its symptoms.

Future Directions

The field of VNS for PTSD is at an inflection point. The convergence of a robust preclinical foundation, promising small-scale clinical results, and the unprecedented findings of the Powers et al. (2025) trial has generated considerable momentum.

Key priorities for the next phase of research include:

- Phase 2 and 3 RCTs — The ongoing double-blind trial of implanted VNS paired with prolonged exposure therapy at UT Dallas and Baylor, and larger non-invasive VNS trials, will be critical for establishing efficacy
- Biomarker development — Identifying objective predictors of VNS response (baseline HRV, inflammatory markers, neuroimaging signatures) could enable personalised treatment
- Home-based protocols — Self-administered taVNS or tcVNS used daily between therapy sessions, potentially extending the window of neuroplasticity
- Combination strategies — Exploring whether VNS can enhance the effects of other evidence-based therapies beyond prolonged exposure, including cognitive processing therapy and EMDR
- Mechanism studies — Further delineating the relative contributions of noradrenergic, serotonergic, and cholinergic pathways to VNS's therapeutic effects in PTSD-specific populations

Summary

PTSD represents a disorder where the neurobiology of fear, autonomic regulation, inflammation, and stress hormone function converge — and where the vagus nerve sits at the intersection of each of these systems. The scientific rationale for VNS in PTSD is not merely theoretical: it is grounded in decades of research on fear extinction neuroscience, confirmed by preclinical studies demonstrating that VNS enhances extinction learning and reverses PTSD-like phenotypes, and now supported by clinical evidence showing that VNS reduces PTSD symptoms, attenuates inflammatory and autonomic stress responses, and — in the most striking result to date — may produce complete diagnostic remission when paired with exposure therapy.

The evidence is still early-stage. Sample sizes are small, large-scale confirmatory trials are needed, and optimal protocols remain to be defined. But the trajectory of this field — from Kilgard and Noble's first rat studies to Powers' landmark human trial — represents one of the most scientifically coherent translational programmes in psychiatric neuroscience. The question is no longer whether VNS can modulate the fear circuit. It is whether it can do so reliably, at scale, and with lasting benefit for the millions of people living with this devastating condition.

---

References

Bottari, S.A., Lamb, D.G. et al. (2024). Preliminary evidence of transcutaneous vagus nerve stimulation effects on sleep in veterans with post-traumatic stress disorder. Journal of Sleep Research, 33(1), e13823.

Bottari, S.A., Lamb, D.G. et al. (2025). Optimizing transcutaneous vagus nerve stimulation parameters for sleep and autonomic function in veterans with PTSD. SLEEP, 48(3), zsae286.

Bremner, J.D. et al. (2021). Transcutaneous cervical vagal nerve stimulation in patients with PTSD: a pilot study of effects on PTSD symptoms and interleukin-6 response to stress. Journal of Affective Disorders Reports, 6, 100190.

Bremner, J.D. et al. (2023). Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with PTSD: a pilot study. Journal of Psychiatric Research, 164, 326–332.

Follesa, P. et al. (2007). Vagus nerve stimulation increases norepinephrine concentration and the gene expression of BDNF and bFGF in the rat brain. Brain Research, 1179, 28–34.

Gurel, N.Z. et al. (2020). Transcutaneous cervical vagal nerve stimulation reduces sympathetic responses to stress in PTSD: a double-blind, randomised, sham-controlled trial. Neurobiology of Stress, 13, 100264.

Lamb, D.G. et al. (2017). Non-invasive vagal nerve stimulation effects on hyperarousal and autonomic state in patients with PTSD. Frontiers in Medicine, 4, 124.

Levi, O. et al. (2022). Treatment effectiveness of military-related PTSD: a systematic review and meta-analysis. Clinical Psychology: Science and Practice, 29(2), 115–131.

Michopoulos, V. et al. (2017). Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond. Neuropsychopharmacology, 42(1), 254–270.

Noble, L.J. et al. (2017). Effects of vagus nerve stimulation on extinction of conditioned fear and post-traumatic stress disorder symptoms in rats. Translational Psychiatry, 7(8), e1217.

Noble, L.J. et al. (2019). Vagus nerve stimulation reverses the extinction impairments in a model of PTSD with prolonged and repeated trauma. Stress, 22(4), 530–536.

Noble, L.J. et al. (2022). Timing of vagus nerve stimulation during fear extinction determines efficacy in a rat model of PTSD. Scientific Reports, 12, 17673.

Noble, L.J. et al. (2024). Optogenetic inhibition of the locus coeruleus blocks VNS-induced enhancement of extinction of conditioned fear in rats. Learning & Memory, 31(12), a053941.

Peña, D.F. et al. (2014). Vagus nerve stimulation enhances extinction of conditioned fear and modulates plasticity in the pathway from the vmPFC to the amygdala. Frontiers in Behavioral Neuroscience, 8, 327.

Powers, M.B., Hays, S.A., Kilgard, M.P. et al. (2025). Vagus nerve stimulation therapy for treatment-resistant PTSD. Brain Stimulation, 18(3), 665–675.

Tracey, K.J. (2002). The inflammatory reflex. Nature, 420(6917), 853–859.

Wittbrodt, M.T. et al. (2020). Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts. Brain Stimulation, 13(5), 1333–1348.

Wittbrodt, M.T. et al. (2020). Transcutaneous vagal nerve stimulation blocks stress-induced activation of IL-6 and IFN-gamma in PTSD. Brain, Behavior, and Immunity — Health, 9, 100138.

Yakunina, N. et al. (2017). Optimization of transcutaneous vagus nerve stimulation using functional MRI. Neuromodulation, 20(3), 290–300.